Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...
Central Nervous System Disorders is under clinical development by Neuroplast and currently in Phase I for Amyotrophic Lateral Sclerosis.
Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...
Acetylcysteine zidrimer is under clinical development by Orpheris and currently in Phase II for Amyotrophic Lateral Sclerosis.
BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Update on Planned Phase 3b Trial of NurOwn® in ALS On December 30, 2024, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) conducted an investor ...
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
Calico, Google's anti-aging subsidiary, has announced disappointing results from its first-ever drug trial. The experimental ...
GlobalData on MSN3d
Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trialDenali Therapeutics has reported that its Phase II/III HEALEY ALS Platform trial of DNL343 for ALS failed to meet its primary endpoint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback